Abraxis
Celgene completes Abraxis takeover
October 15, 2010Research and Development, Sales and Marketing Abraxane, Abraxis, Celgene, mergers and acquisitions, oncology
Celgene has completed its acquisition of Abraxis BioScience for cash and stock totalling $2.9 billion. The takeover gives the cancer …
Manufacturing news in brief
November 30, 2009Manufacturing and Production Abraxis, DSM, Hovione, Lonza
Pharmafocus’ round-up of developments in the pharmaceutical manufacturing sector includes new contracts for CMOs Lonza and DSM, facility news for …
Abraxis Biosciences launches Abraxane in Europe
January 2, 2009Sales and Marketing Abraxis, Cancer, EU
US biotech company Abraxis BioScience has launched its innovative breast cancer treatment Abraxane in Europe. The drug is a variant …
College Hill to promote Abraxis ‘nanoparticle’ drug
December 10, 2008Medical Communications Abraxis, College Hill
Abraxis Bioscience has appointed PR agency College Hill to promote its cancer drug Abraxane in Europe. The albumin-bound 'nano-particle' chemotherapeutic …
Latest content
